AU2001270454A1 - Tablet obtained by direct compression comprising 4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid as active ingredient - Google Patents

Tablet obtained by direct compression comprising 4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid as active ingredient

Info

Publication number
AU2001270454A1
AU2001270454A1 AU2001270454A AU7045401A AU2001270454A1 AU 2001270454 A1 AU2001270454 A1 AU 2001270454A1 AU 2001270454 A AU2001270454 A AU 2001270454A AU 7045401 A AU7045401 A AU 7045401A AU 2001270454 A1 AU2001270454 A1 AU 2001270454A1
Authority
AU
Australia
Prior art keywords
hydroxybutylidene
amino
active ingredient
direct compression
bisphosphonic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001270454A
Inventor
Dagmar Jasprova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Leciva AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=5471285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001270454(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leciva AS filed Critical Leciva AS
Publication of AU2001270454A1 publication Critical patent/AU2001270454A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Abstract

A tablet, obtainable by direct comprising the active ingredient 4-amino-1-hydroxybutylidene-1,1-bis-phosphonic (alendronic) acid or its pharmaceutically acceptable salts in an amount of 5 to 140 mg, based on the pure acid, a dry binder, a disintegrating agent, a lubricant, the tablet comprising, as the diluent, a combination of at least two diluents except lactose.
AU2001270454A 2000-07-11 2001-06-29 Tablet obtained by direct compression comprising 4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid as active ingredient Abandoned AU2001270454A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CZ2000-2567 2000-07-11
CZ20002567A CZ289261B6 (en) 2000-07-11 2000-07-11 Tablet that can be produced by direct tabletting, containing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid as active compound and process for producing thereof
PCT/CZ2001/000037 WO2002003963A1 (en) 2000-07-11 2001-06-29 Tablet obtained by direct compression comprising 4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid as active ingredient

Publications (1)

Publication Number Publication Date
AU2001270454A1 true AU2001270454A1 (en) 2002-01-21

Family

ID=5471285

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001270454A Abandoned AU2001270454A1 (en) 2000-07-11 2001-06-29 Tablet obtained by direct compression comprising 4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid as active ingredient

Country Status (17)

Country Link
US (1) US7198802B2 (en)
EP (1) EP1299088B1 (en)
AT (1) ATE331502T1 (en)
AU (1) AU2001270454A1 (en)
BG (1) BG107520A (en)
CA (1) CA2415630A1 (en)
CZ (1) CZ289261B6 (en)
DE (1) DE60121166D1 (en)
EE (1) EE200300017A (en)
HR (1) HRP20020735A2 (en)
HU (1) HUP0301072A3 (en)
PL (1) PL360872A1 (en)
RU (1) RU2279273C2 (en)
SK (1) SK283249B6 (en)
UA (1) UA73784C2 (en)
WO (1) WO2002003963A1 (en)
YU (1) YU77702A (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6827718B2 (en) 2001-08-14 2004-12-07 Scimed Life Systems, Inc. Method of and apparatus for positioning and maintaining the position of endoscopic instruments
EP1499295A4 (en) * 2002-04-05 2006-04-05 Penwest Pharmaceuticals Co Sustained release metoprolol formulations
GR1004331B (en) * 2002-10-07 2003-09-05 Verisfield (Uk) Ltd New pharmaceutical compositions that contain a salt of alendronic acid.
EP1781258A1 (en) * 2004-08-20 2007-05-09 Mepha AG Formulations of bisphosphonates
WO2006046100A1 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Pharmaceutical composition of alendronic acid
WO2006054165A1 (en) * 2004-11-19 2006-05-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of alendronic acid and processes for their preparation
JP5424642B2 (en) * 2005-10-27 2014-02-26 ニクリス アーゲー Implant and manufacturing method thereof
FR2918567B1 (en) * 2007-07-11 2012-08-03 Pf Medicament STABLE PHARMACEUTICAL COMPOSITION OF A WATER SOLUBLE SALT OF VINORELBINE.
MX2011002016A (en) * 2008-08-22 2011-05-19 Wockhardt Research Center Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof.
EA201190243A1 (en) * 2009-05-19 2013-01-30 Гриндекс, Э Джоинт Сток Кампани STABLE PHARMACEUTICAL COMPOSITION OF FLUDARABIN PHOSPHATE
DK2512455T3 (en) 2009-12-18 2014-03-24 Frieslandcampina Nederland Holding B V Co-treated tablet adjuvant composition, its preparation and use
WO2023025672A1 (en) 2021-08-25 2023-03-02 Basf Se Direct tableting auxiliary composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
EP0697890A1 (en) * 1993-05-15 1996-02-28 Roche Diagnostics GmbH More easily biologically absorbed tablet containing dichloromethylene diphosphonic acid as the active agent
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
KR20010005746A (en) 1997-03-26 2001-01-15 더글라스이.리디치 Chemically and thermally stable norastemizole formulations
HUP0300419A3 (en) * 2000-04-07 2005-07-28 Pfizer Prod Inc Estrogen agonist/antagonist metabolites, pharmaceutical compositions containing them and their use

Also Published As

Publication number Publication date
PL360872A1 (en) 2004-09-20
WO2002003963A1 (en) 2002-01-17
YU77702A (en) 2006-05-25
UA73784C2 (en) 2005-09-15
CZ20002567A3 (en) 2001-12-12
BG107520A (en) 2003-06-30
SK5112001A3 (en) 2002-02-05
US20030161878A1 (en) 2003-08-28
RU2279273C2 (en) 2006-07-10
DE60121166D1 (en) 2006-08-10
EE200300017A (en) 2004-10-15
HUP0301072A3 (en) 2005-07-28
ATE331502T1 (en) 2006-07-15
SK283249B6 (en) 2003-04-01
HRP20020735A2 (en) 2004-12-31
CA2415630A1 (en) 2002-01-17
CZ289261B6 (en) 2001-12-12
EP1299088A1 (en) 2003-04-09
EP1299088B1 (en) 2006-06-28
HUP0301072A2 (en) 2003-08-28
US7198802B2 (en) 2007-04-03

Similar Documents

Publication Publication Date Title
AU2001270454A1 (en) Tablet obtained by direct compression comprising 4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid as active ingredient
MY148680A (en) Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
MY154010A (en) Rapidly disintegrable solid preparation
AU2509895A (en) Fluoxetine pharmaceutical formulations
NZ507271A (en) Fast disintegrating tablets
WO2004012700A3 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
PE20001036A1 (en) BIOADHESIVE TABLETS FOR PROGRESSIVE HYDRATION AND METHODS FOR THEIR PREPARATION AND USE
RS50876B (en) Use of flibanserin in the treatment of sexual disorders
JP2002511411A5 (en)
CA2422359A1 (en) Combretastatin a-4 phosphate prodrug salts with nitrogen-containing compounds
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
CA2360220A1 (en) Oxadiazole compounds and compositions for delivering active agents
CA2164776A1 (en) Pharmaceutical, orally applicable composition
CA2326339A1 (en) Use of dexmedetomidine for icu sedation
RU2003102448A (en) TABLET RECEIVED BY DIRECT PRESSING, CONTAINING 4-AMINO-1-HYDROXIBUTYLIDENE-1,1-BISPHOSPHONIC ACID AS AN ACTIVE INGREDIENT
WO2000054780A3 (en) Corticosteroid formulation
AU1945495A (en) Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds
BRPI9916820B8 (en) a composition comprising 9 [2 [[bis [(pivaloyloxy) methyl] phosphono] methoxy] ethyl] adenine, tablet or capsule and method
EP1219296A4 (en) Sebum production inhibitors
WO2001013895A3 (en) Controlled-release sedative-hypnotic compositions and methods related thereto
CA2399709A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
CA2376847A1 (en) Complex of eletriptan and a cyclodextrin derivative
BG104692A (en) Extended release tiagabine formulation
AU2002350417A1 (en) Soil compacter for connection of a tool